These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 31340964)

  • 1. Persistence with dual antiplatelet therapy after percutaneous coronary intervention for ST-segment elevation acute coronary syndrome: a population-based cohort study in Catalonia (Spain).
    Ribera A; Ferreira-Gonzalez I; Marsal JR; Oristrell G; Faixedas MT; Rosas A; Tizón-Marcos H; Rojas S; Labata C; Cardenas M; Homs S; Tomas-Querol C; Garcia-Picart J; Gomez-Hospital JA; Pijoan JI; Masotti M; Mauri J; Garcia Dorado D;
    BMJ Open; 2019 Jul; 9(7):e028114. PubMed ID: 31340964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
    Hahn JY; Song YB; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Kim J; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC;
    Lancet; 2018 Mar; 391(10127):1274-1284. PubMed ID: 29544699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-based cohort study.
    Green A; Pottegård A; Broe A; Diness TG; Emneus M; Hasvold P; Gislason GH
    BMJ Open; 2016 May; 6(5):e010880. PubMed ID: 27173812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population-based cohort study.
    Angerås O; Hasvold P; Thuresson M; Deleskog A; ÖBraun O
    Scand Cardiovasc J; 2016; 50(2):99-107. PubMed ID: 26564402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends of prescribing adherence of antiplatelet agents in Hong Kong patients with acute coronary syndrome: a 10-year retrospective observational cohort study.
    Lam AS; Yan BP; Lee VW
    BMJ Open; 2020 Dec; 10(12):e042229. PubMed ID: 33273050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of dual antiplatelet therapy and associated outcomes following percutaneous coronary intervention for acute myocardial infarction: contemporary practice insights from the Canadian Observational Antiplatelet Study.
    Russo JJ; Goodman SG; Bagai A; Déry JP; Tan MK; Fisher HN; Zhang X; Zhu YE; Welsh RC; Siega AD; Kokis A; Wong BYL; Henderson M; Lutchmedial S; Lavi S; Mehta SR; Yan AT;
    Eur Heart J Qual Care Clin Outcomes; 2017 Oct; 3(4):303-311. PubMed ID: 29044393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
    Wimmer NJ; Dufour AB; Cho K; Gagnon DR; Quach L; Ly S; Do JM; Ostrowski S; Michael Gaziano J; Faxon DP; Kinlay S
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1176-1184. PubMed ID: 27860195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022.
    Ozaki Y; Hara H; Onuma Y; Katagiri Y; Amano T; Kobayashi Y; Muramatsu T; Ishii H; Kozuma K; Tanaka N; Matsuo H; Uemura S; Kadota K; Hikichi Y; Tsujita K; Ako J; Nakagawa Y; Morino Y; Hamanaka I; Shiode N; Shite J; Honye J; Matsubara T; Kawai K; Igarashi Y; Okamura A; Ogawa T; Shibata Y; Tsuji T; Yajima J; Iwabuchi K; Komatsu N; Sugano T; Yamaki M; Yamada S; Hirase H; Miyashita Y; Yoshimachi F; Kobayashi M; Aoki J; Oda H; Katahira Y; Ueda K; Nishino M; Nakao K; Michishita I; Ueno T; Inohara T; Kohsaka S; Ismail TF; Serruys PW; Nakamura M; Yokoi H; Ikari Y;
    Cardiovasc Interv Ther; 2022 Jan; 37(1):1-34. PubMed ID: 35018605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry.
    Ge Z; Baber U; Claessen BE; Farhan S; Chandrasekhar J; Li SX; Sartori S; Kini AS; Rao SV; Weiss S; Henry TD; Vogel B; Sorrentino S; Faggioni M; Kapadia S; Muhlestein B; Strauss C; Toma C; DeFranco A; Effron MB; Keller S; Baker BA; Pocock S; Dangas G; Mehran R
    Catheter Cardiovasc Interv; 2019 Feb; 93(3):E112-E119. PubMed ID: 30351514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Update ESC-Guideline 2017: Dual Antiplatelet Therapy].
    Massberg S; Polzin A
    Dtsch Med Wochenschr; 2018 Aug; 143(15):1090-1093. PubMed ID: 30060279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
    Christ G; Siller-Matula JM; Francesconi M; Dechant C; Grohs K; Podczeck-Schweighofer A
    BMJ Open; 2014 Oct; 4(10):e005781. PubMed ID: 25361837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of Clopidogrel-Based Dual Antiplatelet Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention　- A Real-World Observation in Taiwan From 2012 to 2015.
    Li YH; Chiu YW; Cheng JJ; Hsieh IC; Lo PH; Lei MH; Ueng KC; Chiang FT; Sung SH; Kuo JY; Chen CP; Lai WT; Lee WL; Chen JH;
    Circ J; 2019 May; 83(6):1317-1323. PubMed ID: 31061379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
    Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
    Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.
    Mehran R; Baber U; Steg PG; Ariti C; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Berger PB; Iakovou I; Dangas G; Waksman R; Antoniucci D; Sartori S; Krucoff MW; Hermiller JB; Shawl F; Gibson CM; Chieffo A; Alu M; Moliterno DJ; Colombo A; Pocock S
    Lancet; 2013 Nov; 382(9906):1714-22. PubMed ID: 24004642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study on the application of the current European guidelines for the management of acute coronary syndrome without elevation of ST segment (NSTEMI) in the Emergency Department setting in the Italian region Lazio.
    Valli G; De Marco F; Spina MT; Valeriano V; Rosa A; Minerva V; Mirante E; Ruggieri MP; Pugliese FR;
    Monaldi Arch Chest Dis; 2014 Dec; 82(4):175-82. PubMed ID: 26562982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
    Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
    Gargiulo G; Ariotti S; Santucci A; Piccolo R; Baldo A; Franzone A; Magnani G; Marino M; Esposito G; Windecker S; Valgimigli M
    JACC Cardiovasc Interv; 2016 Sep; 9(17):1780-9. PubMed ID: 27544007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial.
    Lee JM; Cho DK; Hahn JY; Song YB; Park TK; Oh JH; Lee JB; Doh JH; Kim SH; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC
    Am Heart J; 2016 Dec; 182():1-8. PubMed ID: 27914488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of pre-procedural dual antiplatelet therapy on periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions with adjunctive tirofiban.
    Verdoia M; Pergolini P; Barbieri L; Rolla R; Nardin M; Negro F; Suryapranata H; De Luca G;
    Thromb Res; 2018 Apr; 164():17-23. PubMed ID: 29475177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-Year Survival After ST-Segment-Elevation Myocardial Infarction in Relation With Prehospital Administration of Dual Antiplatelet Therapy.
    Danchin N; Puymirat E; Cayla G; Cottin Y; Coste P; Gilard M; Goldstein P; Braun F; Belle L; Montalescot G; Ferrières J; Schiele F; Simon T;
    Circ Cardiovasc Interv; 2018 Sep; 11(9):e007241. PubMed ID: 30354592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.